"In a systematic review and individual patient meta-analysis reported in The Lancet, the NSCLC Meta-analysis Collaborative Group found that neoadjuvant therapy for non–small cell lung cancer (NSCLC) was associated with a significant 13% reduction in risk of death. Significant benefits in recurrence-free survival and time to distant recurrence were also observed...
"Preoperative chemotherapy was associated with a 13% improvement in overall survival.
"Preoperative chemotherapy was associated with a 15% improvement in recurrence-free survival and a 31% improvement in time to distant recurrence."
Editor's Note: "neoadjuvant therapy" refers to chemotherapy given before tumor removal surgery in the hopes of improving the success of the surgery.